2183. Porin Mutations Potentiate the in Vitro Synergy of Meropenem-Vaborbactam (MVB), but not Ceftazidime-Avibactam (CZA) in Combination with Other Antibiotics against KPC-producin...

por Rogers, Tara M, Kline, Ellen G, Squires, Kevin M, Jones, Chelsea, Shields, Ryan K
Publicado 2023

Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clini...

por Rogers, Tara M, Kline, Ellen G, Griffith, Marissa P, Jones, Chelsea E, Rubio, Abigail M, Squires, Kevin M, Shields, Ryan K
Publicado 2023

Mutations in ompK36 differentially impact in vitro synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing Klebsiella...

por Rogers, Tara M, Kline, Ellen G, Griffith, Marissa P, Jones, Chelsea E, Rubio, Abigail M, Squires, Kevin M, Shields, Ryan K
Publicado 2023